eva gallardo, md medical manager, biocompatibles uk
DESCRIPTION
Drug Eluting Bead: Advanced Applications Colorectal Metastases Neuroendocrine Metastases Combination with RFA. Eva Gallardo, MD Medical Manager, Biocompatibles UK. DEB: Clinical Programme. Primary Liver Cancer. Colorectal Metastases. Very Early/Early Stage Prior to resection - PowerPoint PPT PresentationTRANSCRIPT
EC915
Eva Gallardo, MDMedical Manager, Biocompatibles UK
Drug Eluting Bead: Advanced Applications
Colorectal MetastasesNeuroendocrine Metastases
Combination with RFA
EC915
Doxorubicin Bead Irinotecan Bead
Primary Liver Cancer Colorectal MetastasesVery Early/Early Stage Prior to resection Bridge to transplant RFA + PRECISION TACE
Intermediate Stage Precision I Precision II Precision V
Advanced Stage Sorafenib + PRECISION TACE
Secondary Liver Cancer Other Primary Cancers
Renal Breast Melanoma Gastric Neuroendocrine Cholangiocarcinoma Sarcoma
Early CT Lines
Late Stage
DEB: Clinical Programme
EC915
Investigators: Camillo Aliberti, MD Giammaria Fiorentini, MD
Department of Diagnostic and Interventional Radiology,Delta Hospital AUSL Ferrara, Ferrara Italy
Department of Oncology, General Hospital San Giuseppe, Empoli, Florence, Italy
PRECISION TACE in treatment of Colorectal Metastases
EC915
Advanced Colorectal Cancer • The liver is the most common site of metastatic disease.
• 15-30% of patients will have synchronous liver metastases at the time of diagnosis. Up to 60% will develop hepatic metastases during the course of their disease
• Metastatic disease in the liver is the primary determinant of survival in patients with colorectal cancer
• Low (around 20%) response rates to 5-FU containing chemotherapy regimens
EC915
Median Survival in First Line Phase III StudiesMonths
Best supportive care 5
Biomodulation of 5-FU Piedbois JCO 1992 10
Saltz NEJM 2001 (IFL) 14 Irinotecan/5-FU/LV Goldberg JCO 2004 (IFL) 15
17 Douillard Lancet 2000 (Folfiri)
De Gramont JCO 2000 (Folfox) 16 Oxaliplatin/5-FU/FA
Goldberg JCO 2004 (Folfox) 20
23 FOLFOXIRI
24.4 Hoschster ASCO 2006 - TREE2 Oxali/Bev + salvage CP11 2 drugs+biologic+salvage
**subgroup
Hurwitz NEJM 2004 IFL/Bev + salvage Oxali 25.1
BMJ 1993
FOLFOX/FOLFIRI 22Tournigand JCO 2004 sequential 2 drugs
Falcone ASCO 2006 concurrent 3 drugs - no biologics
EC915
Rationale for Chemoembolization treatment in metastatic CRC
• Blood supply from hepatic artery
• Maximize tumour cell kill while minimizing toxicity to normal tissues (heavily systemically treated patients)
• Increase tumour response throughout increased drug delivery into tumour
• Increase resectability rates
EC915
Disease control after Chemoembolization
• n= 207 • Local tumour control:
– Partial response: 12%, stable: 51%, progression: 37%
• Survival rates: – 1y: 62%, 2y: 38%
• Median survival times:– From diagnosis: 3.4y, from TACE: 1.34y
Prof T Vogl, ASCO 2007
EC915
• 62 patients (M/F = 42/20), median aged 64.6 (range 42-85) • Not operable and pretreated at least two lines of chemo
(range 2-6) • Measurable lesions with size > 1cm• Tumour burden <70% of liver volume• Presence of minimal extrahepatic sites • Performance Status: 0-2 (WHO criteria), life expectancy >3
months, age < 86 years • Normal or 2xN bilirubine
Irinotecan Bead in Advanced Colorectal Cancer: Patient
Selection
EC915
• Diagnostic angiography (DSA) was performed
• Under fluoroscopic guidance, a solution of DC beads loaded with Irinotecan and mixed with non-ionic contrast was injected into: RHA 39%, LHA 36%, RHA & LHA 25%
• Maximum dose 4 ml (2ml of 100-300mm and 2ml of 300-500mm) with 200mg of Irinotecan
• 2-3 TACE 4 weeks
Irinotecan Bead in Advanced Colorectal Cancer: Methods
EC915
• 138 TACE procedures
• 48 with 100mgr Irinotecan into 2ml DC Bead
• 98 with 200mgr Irinotecan into 4ml DC Bead (no significant toxicity observed)
• 100% technical success
• One case of acute pancreatitis, resolved spontaneously
Irinotecan Bead in Advanced Colorectal Cancer: Feasibility
EC915
Postembolization-syndrome
RUQP (G2-G3) 100%
Fever (G2) 90%
Nausea and Vomiting (G2-G3)
100%
Increased Transaminases (G2-G3)
80% 0
5
10
15
20
25
30
35
40
Procedures
Pain Vomiting Fever Asthenia
Irinotecan Bead in Advanced Colorectal Cancer: Toxicity
EC915
• Prophylactic treatment against nausea
• Tropisetron 5mg, 1 vial before TACE and at +6 hours,Prednisone 25mg tb 08.00 am and 08.00 pm day 0,+1,+2,+3,+4,+5
• Prophylactic treatment against pain
• Morphine 10mg, 1 vial, 30 minutes before TACE and at +6 hours.
• Intra-arterial Lidocaine 5ml just before TACE.
• Prophylactic treatment against infection
• Cefazolin 2000mg 08.00 am and 08.00 pm day 0,+1,+2
• On day +1, +2 at 08.00 am and 08.00 pm following observed symptoms.
Postembolization-syndrome: Selected Therapy
Irinotecan Bead in Advanced Colorectal Cancer: Toxicity
EC915
• The median follow-up was 15.4 months
• 1 month CT scan showed reduction of metastatic CE 85%, range 75-100% in all patients
• RECIST at 3 months: 78%
• 55/62 pts (90%) declared a general improvement of QoL lasting 6.5 months, range 3-12
Irinotecan Bead in Advanced Colorectal Cancer: Response to
Treatment
EC915
• Median survival not reached at 22 months
• Median Free Time from symptoms 5.3 (5-20 months)
• Median Time to further chemoteraphy 6.3 (5-22 months )
0
10
20
30
40
50
60
70
80
90
100
0 2 4 6 8 10 12 14 16 18 20 22time months
surv
ival
(%
)
Irinotecan Bead in Advanced Colorectal Cancer: Survival
EC915
18 months after TACE
Irinotecan Bead in Advanced Colorectal Cancer: Cases
EC915
02.2005 09.2005
6 months after TACE
Irinotecan Bead in Advanced Colorectal Cancer: Cases
EC915
• TACE with Irinotecan DC Bead could be proposed as palliative therapy for unresectable pretreated Liver Metastases from CRC
• Promising preliminary results should be confirmed in further studies in larger population
Irinotecan Bead in Advanced Colorectal Cancer: Conclusion
EC915
Principal Investigator: Thierry De Baere, MDChief of Interventional Radiology Department
Institut de Cancérologie Gustave Roussy - Villejuif - France
Neuroendocrine Metastasis
EC915
Neuroendocrine Tumours
• Variety of primaries with shared characteristics including hormone secretion, high vascularization and somatostatin receptor expression
• Tumours arise most often from the gastro-intestinal tract and mainly the small bowel
• The malignancy grade and the stage at diagnosis are the two major prognostic factors
EC915
Management Protocol
EC915
Reported HAE and HACE Series
Carcinoid tumours Islet cell carcinomas
HACE HAE HACE HAE
Study% CR + PR (no.) Study
% CR + PR (no.) Study % CR + PR (no.) Study
% CR + PR (no.)
Hazarizadeh et al., 1992 50.0 (4/8) Hanssen et al., 1989
71.0 (5/7) Carrasco et al., 1983
100.0 (3/3) Carrasco et al., 1983
50.0 (3/6)
Rusznieweski et al., 1993] 33.3 (6/18) Moertel et al., 1994
69.6 (16/23) Mavligit et al., 1993
80.0 (4/5) Moertel et al., 1994
82.0 (14/17)
Therasse et al., 1993 35.0 (6/17) Wangberg et al., 1996
42.5 (17/40) Kim et al., 1999
50.0 (7/14) Eriksson et al., 1998
17.0 (2/12)
Kim et al., 1999 25.0 (4/16) Eriksson et al., 1998
38.0 (11/29) Dominguez et al., 2000
57.0 (4/7) Ajani et al., 1988 60.0 (12/20)
Dominguez et al., 2000 50,0 (4/8) Carrasco et al., 1983
83.0 (5/6) Rusznieweski et al., 1993
0.0 (0/5)
Roche et al., 2003 43.0 (6/14) Loewe et al., 2003 73.0 (16/22)
Drougas et al., 1998 6.7 (1/15)
Average 32.0 (31/96) Average 55.0 (70/127)
Average 53.0 (18/34) Average 56.0 (31/55)
EC915
Doxorubicin Bead in NET:Materials and Methods
• 20 patients with liver metastases from low-grade GEP tumour
• Progressive liver disease on two subsequent imaging studies according to RECIST criteria
• Disease predominant to the liver
• Up to 4ml DC Bead 500-700mm loaded with up to 100mg doxorubicin
• Concomitant treatment with long-acting ST analog
EC915
Doxorubicin Bead in NET:Results
• 34 sessions (6 unilobar, 14 bilobar)
• RECIST 3M: – 16/20 (80%) partial response– 3/20 (10%) stable disease– 1/20 (15%) progressive disease
• After a median follow-up of 15 months (6-24), disease remained controlled without tumour progression in 45%
• 1 patient become resectable
Progression
161520
0%10%
20%30%
40%50%60%
70%80%
90%100%
0 6 12 18 24Months since treatment
Pro
gre
ssio
n r
ate
Patients at risk
At 12 months : 47% (95%CI = 23% - 72%)
Median Time to Progression: 15 months
EC915
• Post-embolisation syndrome:– < 7 days in 67% sessions– > 7 days in 22% sessions– No symptoms in 11% sessions
• Hypodense subsegmental peripheral areas (TACE-induced necrotic liver tissue?) in 5 patients at 1 month CTscan
• 1 death: resected patient due to postoperative septic complications
Doxorubicin Bead in NET:Toxicity
EC915
Doxorubicin Bead in NET:Cases
EC915
Doxorubicin Bead in NET:Cases
EC915
Tumour resected 2 months after PRECISION TACE
Doxorubicin Bead in NET:Cases
EC915
• TACE with doxorubicin bead yielded a 90% response rate in patients with progressive liver metastases from a GEP tumor without severe complications
• These promising preliminary results warrant a comparative study in a larger population
Doxorubicin Bead in NET: Conclusion
EC915
Principal Investigator: Riccardo Lencioni, MDAssociate Professor of Diagnostic and Interventional
RadiologyDepartment of Oncology, Transplants, and Advanced
Technologies in Medicine – Pisa University, Italy
Combined PRECISION TACE/RFA: Results and Outcome
EC915
HCC
PST 0-2, Child-Pugh A-BPST > 2
ChildPugh C
Very earlystage
Single< 2 cm
Earlystage
Single or 3 < 3 cmPS 0
Advancedstage
Portal invasionN1 – M1PS 1-2
Terminalstage
Intermediatestage
MultinodularPS 0
BSC
PST 0Child
Pugh A
New agentsResection Transplant Ablation TACE
SingleNo portal HT
Normal bilirubin
Associated diseases
No Yes
EC915
Bio-Heat Equation
ct
2 Qcs
4r2
r
cb Io
216 2r4
Coagulation
Necrosis
Energy
Deposited
Tissue
Interactions
Heat
Loss= x -
RFA: Inherent Limitations
modified from Goldberg SN et al, AJR 2000
EC915
Vessel
Sub-lethal heating(45-50 °C)
50 °C
RFA: Inherent Limitations
EC915
modified from Ahmed et al, Radiology 2005
RFA plus Doxorubicin vs RFA Alonein Animal Tumour Models
EC915
RF-induced coagulation
Increased peripheral necrosis
Normal tissue
modified from Ahmed et al, Radiology 2005
RFA plus Doxorubicin vs RFA Alonein Animal Tumour Models
EC915
• Rossi S, Radiology 2000• Yamasaki T, Cancer 2001• Yamakado K et al,JVIR 2002• Gasparini D, Radiol Med 2002 • Akamatsu M, Liver Int 2004• Luo BM, World J Gastroenterol 2005• Maluccio M, JVIR 2005• Shen SQ, Hepatogastroenterology 2005• Yamasaki T, J Gastroenterol 2005• Liu YM, World J Gastroenterol 2006• Veltri A, Eur Radiol 2006• Kurokohchi K, Oncol Rep 2006• Lim HS, AJR 2006• Takaki H, JVIR 2007• Kobayahi M, Liver Int 2007• Helmberger T, Digestion 2007• Wang JB, Qual Life Res 2007• Liao GS, Eur J Surg Oncol 2008• Fuke H, Aliment Pharmacol Ther 2008• Yamakado K, Radiology 2008
Combined TACE / TAE and RFA in HCC
20 clinical studies
all “support” the combined
approach
EC915
Lencioni R et al, J Hepatol 2008 (in press)
DC Bead (Biocompatibles, UK): embolic microsphere that has the ability to actively sequester doxorubicin hydrochloride from solution and release it in a controlled and sustained fashion
Hypothesis: intra-arterial administration of doxorubicin eluting bead to HCC tumours incompletely killed by RFA induces necrotic phenomena in peripheral areas exposed to sub-lethal heating, improving tumour response
DEB-Enhanced RFA of HCC: A Pilot StudyBackground / Hypothesis
EC915
DEB-Enhanced RFA of HCC: A Pilot StudyDesign / Enrollment Criteria
Prospective, intention-to-treat, single-arm pilot study
Primary endpoints: safety and tumour response
Inclusion criteria
- Adult patient with single HCC 3.0 – 7.0 cm - Residual viable tumour at CT / MRI 1-2 hrs after RFA- Child-Pugh class A, ECOG 0, ASA ≤ 3- PT ratio > 50%, platelets > 50,000/mm3
Exclusion criteria
- Eligibility for liver resection or transplantation- Vascular invasion / extrahepatic disease- Any previous treatment for HCC
EC915
DEB-Enhanced RFA of HCC: A Pilot StudyMaterials and Methods
20 pts (mean age, 70 ± 6 ) enrolled 09/05 – 11/06
- Tumour diameter 3.3-7.0 cm (mean, 5.0 cm ± 1.4)
Follow-up period 6-20 months (mean, 12 months ± 5)
DC Bead (Biocompatibles) injection < 24 hrs of RFA
- 50 mg doxorubicin in 2 ml of 100-300 μm beads - Additional loads (100-300 / 300-500 µm) if needed
Tumour response: RECIST criteria - EASL amendment
- CR: absence of enhancement at 1-month CT / MRI- Confirmed CR: CR lasting no less than 6 months- OR: confirmed CR target lesion, no new lesions
EC915
61% +
Abl
atio
n V
olum
e (m
m3)
0,000
20,000
40,000
60,000
80,000
100,000
120,000
140,000
160,000
180,000
Standard RFA DEB-Enhanced RFA
DEB-Enhanced RFA of HCC: A Pilot StudyResults – Change in Ablation Volume
EC915
DEB-Enhanced RFA of HCC: A Pilot StudyResults – Clinical Case # 2
Pre-treatment CT
6 cm
EC915
DEB-Enhanced RFA of HCC: A Pilot StudyResults – Clinical Case # 2
MRI after standard RFA
EC915
DEB-Enhanced RFA of HCC: A Pilot StudyResults – Clinical Case # 2
DEB administration
EC915
DEB-Enhanced RFA of HCC: A Pilot StudyResults – Clinical Case # 2
MRI after DEB administration
EC915
15
10
5
CR IR PD
14
6
DEB-Enhanced RFA of HCC: A Pilot StudyResults – Target Tumour Response
CR IR PD
12
6
2
15
10
5
Final Response
(mean follow-up, 1 year)
Initial Response(1-month CT / MRI))
EC915
Target lesions
Table. Overall Response at the End of Follow-Up
New lesions
CR
PR
CR / PR
PD
Note: Numbers are numbers of patients. Overall number of patients: 20.
No
No
Yes
Yes / No
Overall response
CR
PR
PD
No. (%)
10 (50%)
5 (25%)
3 (15%)
2 (10%)
DEB-Enhanced RFA of HCC: A Pilot StudyResults – Overall Response
EC915
0 6 12 18 240
20
40
60
80
100
DEB-enhanced RFA (n = 20)
months
30
100%
DEB-Enhanced RFA of HCC: A Pilot StudyResults – Overall Survival
92%
EC915
DEB-Enhanced RFA of HCC: A Pilot Study
Results – Conclusion• This pilot clinical study provides the first evidence of
the synergy between RF ablation and local delivery of a chemotherapeutic agent in human cancer treatment
• Intraarterial DEB administration substantially increased the effect of RF ablation and did not cause any major complication. DEB-enhanced RF ablation induced a high rate of CR and has potential to become the standard of care for uninodular nonsurgical HCC resistant to standard RF treatment